Pharmacosmos predicts record financial year after launches in US and China

The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.

Tobias Sidelmann Christensen, Vice President and Chief Operating Officer at Pharmacosmos (right) and his father Lars Christensen, who is CEO of the company. | Photo: Pharmacosmos / PR

Pharmacosmos has lit a fire under its dream of becoming an international company by establishing a presence in the US and China through subsidiaries and launching its main product (called Monoferric in the US and Monofer in China) on both markets.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs